4.6 Article

Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration Evidence from the EYE-RISK and European Eye Epidemiology Consortia

Journal

OPHTHALMOLOGY
Volume 126, Issue 3, Pages 393-406

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ophtha.2018.09.045

Keywords

-

Categories

Funding

  1. European Union's Horizon 2020 research and innovation programme [634479]
  2. Laboratoires Thea (Clermont-Ferrand, France)
  3. Fondation Voir et Entendre (Paris, France)
  4. Caisse Nationale de Solidarite pour l'Autonomie (Paris, France)
  5. AIBILI - Novartis Pharma AG
  6. Medical Research Council [MC_PC_13048, G1000143]
  7. Cancer Research UK [C864/A14136]
  8. Research into Ageing [262]
  9. Moorfields Eye Charity fellowship
  10. Richard Desmond Charitable Trust
  11. Department for Health through National Institute for Health Research
  12. Landelijke Stiching voor Blinden en Slechtzienden
  13. Stichting Blindenhulp, Stichting A. F. Deutman Oogheelkunde Researchfonds
  14. Netherlands Organization for Scientific Research (Vidi Innovational Research Award) [016.096.309]
  15. European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013) [310644 MACULA]
  16. Inter-regional grant (Programme Hospitalier de Recherche Clinique [PHRC])
  17. Regional Council of Burgundy
  18. CNRS
  19. Universite de Bourgogne, Regional Council of Burgundy France (PARI Agrale 1)
  20. FEDER (European Funding for Regional Economic Development)
  21. French Government grant [ANR-11-LABX-0021-01-LipSTIC Labex]
  22. Institut National de la Sante et de la Recherche Medicale (Inserm), Paris, France
  23. Fondation de France
  24. Fondation pour la Recherche Medicale, Paris
  25. Region Languedoc-Roussillon, Montpellier, France
  26. Rhones Poulenc
  27. Horiba ABX Montpellier
  28. Research Institute for Diseases in the Elderly (RIDE)
  29. Ministry of Education, Culture and Science
  30. Ministry for Health, Welfare and Sports, the European Commission (DG XII)
  31. Municipality of Rotterdam
  32. Oogfonds
  33. Landelijke Stichting voor Blinden en Slechtzienden
  34. Novartis Foundation
  35. Netherlands Organisation of Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek [NWO]) Investments [175.010.2005.011, 911-03-012]
  36. Genetic Laboratory of the Department of Internal Medicine, Erasmus Medical Center
  37. Research Institute for Diseases in the Elderly [014-93-015]
  38. Netherlands Genomics Initiative/Netherlands Organisation for Scientific Research/Netherlands Consortium for Healthy Aging [050-060-810]
  39. MaculaFonds
  40. INRA
  41. Department of Epidemiology of Ageing, Paris
  42. Association Retina-France, Toulouse
  43. Essilor
  44. Specia
  45. Centre de Recherche et d'Information Nutritionnelle, Paris
  46. Erasmus Medical Center and Erasmus University, Rotterdam
  47. Netherlands Organization for the Health Research and Development (ZonMw)
  48. MaculaFonds [2015-36]
  49. MRC [MR/K023721/1] Funding Source: UKRI

Ask authors/readers for more resources

Purpose: Genetic and epidemiologic studies have shown that lipid genes and high-density lipoproteins (HDLs) are implicated in age-related macular degeneration (AMD). We studied circulating lipid levels in relationship to AMD in a large European dataset. Design: Pooled analysis of cross-sectional data. Participants: Individuals (N = 30 953) aged 50 years or older participating in the European Eye Epidemiology (E3) consortium and 1530 individuals from the Rotterdam Study with lipid subfraction data. Methods: AMD features were graded on fundus photographs using the Rotterdam classification. Routine blood lipid measurements, genetics, medication, and potential confounders were extracted from the E3 database. In a subgroup of the Rotterdam Study, lipid subfractions were identified by the Nightingale biomarker platform. Random-intercepts mixed-effects models incorporating confounders and study site as a random effect were used to estimate associations. Main Outcome Measures: AMD features and stage; lipid measurements. Results: HDL was associated with an increased risk of AMD (odds ratio [OR], 1.21 per 1-mmol/l increase; 95% confidence interval [CI], 1.14-1.29), whereas triglycerides were associated with a decreased risk (OR, 0.94 per 1-mmol/l increase; 95% CI, 0.91-0.97). Both were associated with drusen size. Higher HDL raised the odds of larger drusen, whereas higher triglycerides decreases the odds. LDL cholesterol reached statistical significance only in the association with early AMD (P = 0.045). Regarding lipid subfractions, the concentration of extra-large HDL particles showed the most prominent association with AMD (OR, 1.24; 95% CI, 1.10-1.40). The cholesteryl ester transfer protein risk variant (rs17231506) for AMD was in line with increased HDL levels (P = 7.7 x 10(-7)), but lipase C risk variants (rs2043085, rs2070895) were associated in an opposite way (P = 1.0 x 10(-6) and P = 1.6 x 10(-4)). Conclusions: Our study suggested that HDL cholesterol is associated with increased risk of AMD and that triglycerides are negatively associated. Both show the strongest association with early AMD and drusen. Extra-large HDL subfractions seem to be drivers in the relationship with AMD, and variants in lipid genes play a more ambiguous role in this association. Whether systemic lipids directly influence AMD or represent lipid metabolism in the retina remains to be answered. (C) 2018 by the American Academy of Ophthalmology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available